Table 2.
Reasons for switching to intravenous golimumab treatment
| Total | 61 |
|---|---|
| Reason for switch | f |
| Loss of efficacy | 52 |
| Patient preference | 2 |
| Insurance coverage | 7 |
f frequency or frequency of observations
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.